510(k) Report

510(k) · Cleared

Cleared

CalprestNG, EasyCal

K191592510(k) SpecialCleared Jul 10, 201926-day reviewClass II21 CFR 866.5180

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Eurospital S.P.A. · NXO Calprotectin, Fecal

Cleared on Jul 10, 2019 as substantially equivalent to K160447 (Eurospital S.P.A., 2016) after a 26-day review. Its family tree reaches back 3 generations to 2006.

Decided
Jul 10, 2019
Review
26 days
Class
Class II
Product code
NXO
Recalls
None
Predicates
1

Its longest line of descent runs back 3 generations to DEN060001 (2006). No later device cites it as a predicate yet.

  1. Root · 3 generations backDEN060001 Phical TestGenova Diagnostics · 2006
  2. 2 generations backK130945 CalprestEurospital S.P.A. · 2014
  3. 1 generation backK160447 Calprest NGEurospital S.P.A. · 2016
  4. This deviceK191592 CalprestNG, EasyCalEurospital S.P.A. · 2019
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−3DEN060001Phical TestGenova Diagnostics2006—
−2K130945CalprestEurospital S.P.A.2014—
−1K160447Calprest NGEurospital S.P.A.2016—
0 (this device)K191592CalprestNG, EasyCalEurospital S.P.A.2019—
FIG. 1 — Lineage of K191592, 2006–2019Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in NXO? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new NXO device

  1. #1 K232057 BÜHLMANN fCAL® turbo and CALEX® Capscore 8.3 · 6 generations · no Class I recall
  2. #2 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K160447Calprest NG
Summary page 5
…Pag. 2 / 9 510(k) Summary 2. Predicate device Calprest®NG (using manual extraction), 510 (k) number K160447. Date of clearance: November 10th, 2016. 3. Device description Calprest®NG is an enzyme-li…
Eurospital S.P.A.2016—

Also cleared against K160447: 3 other devices →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 13 years and passes through 2 companies; a new generation was cleared every 2.8 years on median.
  • None of the 3 ancestors has a recall.
  • 3 other devices also cite its predicate K160447.

How does its category compare?

All NXO devices

NXO Calprotectin, Fecal: FDA decisions, review times, recalls and adverse event reports over 20 years. 2019, this device’s year, is highlighted.

FDA decisions per year · NXO

1in 2024

2014: 12016: 12017: 12018: 32019: 52022: 12023: 12024: 1
2007high 5 (2019) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · NXO

90in 2019

2018: 90 days median2019: 90 days median
2007high 90 (2018)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · NXO

2in 2025

2024: 12025: 2
2007high 2 (2025) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · NXO

1in 2022

2022: 1
2007high 1 (2022) · low 0 (2007)2025

MAUDE reports naming product code NXO, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20141—00
20150—00
20161—00
20171—00
201839000
201959000
20200—00
20210—00
20221—01
20231—00
20241—10
20250—20
20260—0—

What is it indicated for?

CalprestNG is a quantitative ELISA for detecting concentration of fecal calprotectin. CalprestNG can be used as an in vitro diagnostic to aid in the diagnosis of Inflammatory Bowel Diseases (IBD, Crohn’s disease and ulcerative colitis) and to differentiate IBD from Irritable Bowel Syndrome (IBS) in conjunction with other clinical and laboratory findings.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K191592: CalprestNG, EasyCal.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K191592

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026